Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

Targeted inhibition of Rho-associated kinase (ROCK)2 downregulates the proinflammatory T cell response while increasing the regulatory arm of the immune response in animals models of autoimmunity and Th17-skewing human cell culture in vitro. In this study, we report that oral administration of a sel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunol
Egile Nagusiak: Zanin-Zhorov, Alexandra, Weiss, Jonathan M., Trzeciak, Alissa, Chen, Wei, Zhang, Jingya, Nyuydzefe, Melanie S., Arencibia, Carmen, Polimera, Seetharam, Schueller, Olivier, Fuentes-Duculan, Judilyn, Bonifacio, Kathleen M., Kunjravia, Norma, Cueto, Inna, Soung, Jennifer, Fleischmann, Roy M., Kivitz, Alan, Lebwohl, Mark, Nunez, Margarita, Woodson, Johnnie, Smith, Shondra L., West, Robert F., Berger, Mark, Krueger, James G., Ryan, John L., Waksal, Samuel D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AAI 2017
Gaiak:
Cutting Edge
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5421306/
https://ncbi.nlm.nih.gov/pubmed/28389592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1602142
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak